BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20216989)

  • 1. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
    Kozian DH; Lorenz M; März W; Cousin E; Mace S; Deleuze JF
    Thromb Haemost; 2010 May; 103(5):976-83. PubMed ID: 20216989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
    Tàssies D; Roqué M; Monteagudo J; Martorell T; Sionis A; Arzamendi D; Heras M; Reverter JC
    Thromb Res; 2009 Nov; 124(5):614-8. PubMed ID: 19699511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
    Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
    Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
    Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
    Ladenvall C; Gils A; Jood K; Blomstrand C; Declerck PJ; Jern C
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):955-62. PubMed ID: 17272741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
    de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
    Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
    Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
    Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
    Dusse LM; Cooper AJ; Lwaleed BA
    Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
    Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
    Martinez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
    Am J Reprod Immunol; 2009 Dec; 62(6):381-9. PubMed ID: 19895374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
    Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
    Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. +1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss.
    Pruner I; Djordjevic V; Miljic P; Kovac M; Antonijevic N; Rakicevic L; Radojkovic D
    Blood Coagul Fibrinolysis; 2010 Oct; 21(7):679-82. PubMed ID: 20729722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction.
    Akatsu H; Yamagata H; Chen Y; Miki T; Kamino K; Takeda M; Campbell W; Kondo I; Kosaka K; Yamamoto T; Okada H
    Br J Haematol; 2004 Nov; 127(4):440-7. PubMed ID: 15521922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the Thr325Ile and Ala147Thr polymorphisms of the TAFI gene and the risk of venous thromboembolic disease.
    Verdú J; Marco P; Benlloch S; Lucas J
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):494-5. PubMed ID: 18160566
    [No Abstract]   [Full Text] [Related]  

  • 16. Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
    Martínez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
    J Reprod Immunol; 2010 Nov; 86(2):133-40. PubMed ID: 20594598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ; Leebeek FW; Tanck MW; Wouter Jukema J; Kluft C; de Maat MP
    Thromb Haemost; 2003 Jul; 90(1):92-100. PubMed ID: 12876631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
    Bouma BN; Mosnier LO
    Ann Med; 2006; 38(6):378-88. PubMed ID: 17008302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.
    Masini S; Ticconi C; Gravina P; Tomassini M; Pietropolli A; Forte V; Federici G; Piccione E; Bernardini S
    Fertil Steril; 2009 Aug; 92(2):694-702. PubMed ID: 18774564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
    Boffa MB; Koschinsky ML
    Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.